CDRH funded in full
This article was originally published in The Gray Sheet
Executive Summary
House passes the "Agriculture, Rural Development, Food & Drug Administration and Related Agencies Appropriations Act for FY 2006" (HR 2744) June 8, meeting the President's $221 mil. request for CDRH, which would fulfill the estimated MDUFMA funding target, assuming the enactment of "trigger-fix" legislation later this year (1"The Gray Sheet" Feb. 14, 2005, p. 3). Total FDA allotment of $1.5 bil. represents a $36 mil. increase over last year, but falls $14 mil. short of the President's request. An amendment proposed by Rep. Maurice Hinchey (D-N.Y.) and passing via a 218-210 vote would prohibit FDA from granting waivers to advisory panel participants harboring an apparent conflict of interest. Companion legislation is scheduled for mark-up by the Senate Appropriations/Agriculture, Rural Development & Related Agencies Subcommittee June 21 and by full committee June 23...
You may also be interested in...
FDA panel conflicts of interest
Reconciled FY 2006 FDA appropriations bill passes the House Oct. 28 with a "very watered-down" version of an advisory committee conflict-of-interest (CoI) provision, according to Rep. Maurice Hinchey (D-N.Y.), who succeeded in adding a CoI amendment to the original House bill in June. The final language requires that panel member conflicts of interest and waivers for conflicts be posted on FDA's website at least 15 days prior to a meeting or as soon as possible if the conflict is identified closer to the meeting date. Hinchey's amendment would have prohibited FDA from granting CoI waivers (1"The Gray Sheet" June 13, 2005, In Brief)...
CDRH FY 2006 Budget Authority Would Be $165 Mil., With $56 Mil. For Field
FDA enforcement activity will receive 70% of the $6 mil. increase President Bush is requesting for the medical device program in fiscal 2006
Keeping Track: Cancer Approvals From Lumisight Imaging To Adjuvant Alecensa
The US FDA’s approval of Lumicell’s optical imaging agent Lumisight makes a dozen novel approvals in 2024 for the Center for Drug Evaluation and Research.